Holen Sie sich die Stockscreener-App
25.00
5.20%
-1.35
Handel nachbörslich:
25.01
0.01
+0.04%
Schlusskurs vom Vortag:
$26.35
Offen:
$25.74
24-Stunden-Volumen:
163.20K
Relative Volume:
0.91
Marktkapitalisierung:
$413.44M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-8.1967
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
-13.92%
1M Leistung:
+54.01%
6M Leistung:
+237.20%
1J Leistung:
+61.79%
1-Tages-Spanne:
$24.80
$26.23
1-Wochen-Bereich:
$24.25
$30.93
52-Wochen-Spanne:
$5.6652
$32.35
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
25.00 | 443.05M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Key metrics from RAPT Therapeutics Inc.’s quarterly dataPortfolio Performance Report & Verified Chart Pattern Signals - newser.com
What MACD and RSI say about RAPT Therapeutics Inc.Gold Moves & High Accuracy Investment Signals - newser.com
Risk adjusted return profile for RAPT Therapeutics Inc. analyzedEarnings Miss & High Conviction Investment Ideas - newser.com
What indicators show strength in RAPT Therapeutics Inc.Risk Management & Free High Accuracy Swing Entry Alerts - newser.com
Barclays Initiates Coverage of RAPT Therapeutics (RAPT) with Overweight Recommendation - Nasdaq
Why retail investors favor RAPT Therapeutics Inc. stockEarnings Growth Summary & Fast Exit/Entry Strategy Plans - newser.com
Is RAPT Therapeutics Inc. stock a buy for dividend growthJuly 2025 Volume & Stepwise Swing Trade Plans - newser.com
Will RAPT Therapeutics Inc. price bounce be sustainableMarket Sentiment Report & Consistent Income Trade Recommendations - newser.com
Top chart patterns to watch in RAPT Therapeutics Inc.Layoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
What hedge fund moves indicate for RAPT Therapeutics Inc. (0RA) stockTrade Volume Summary & Consistent Profit Alerts - newser.com
Market reaction to RAPT Therapeutics Inc.’s recent newsRate Hike & Reliable Price Breakout Signals - newser.com
Why RAPT Therapeutics Inc. stock is seen as undervalued2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Rapt Therapeutics (NASDAQ:RAPT) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Does RAPT Therapeutics Inc. qualify in momentum factor screening2025 Macro Impact & Breakout Confirmation Trade Signals - newser.com
What drives RAPT Therapeutics Inc 0RA0 stock priceTrade Execution Strategies & Identify Winning Stocks - earlytimes.in
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
How analysts rate RAPT Therapeutics Inc. stock today2025 Institutional Moves & Detailed Earnings Play Strategies - newser.com
How to use a screener to detect RAPT Therapeutics Inc. breakoutsPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Can swing trading help recover from RAPT Therapeutics Inc. lossesWeekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Why RAPT Therapeutics Inc. (0RA0) stock stays on top picksWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock bottoming after sell offQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
Rapt Therapeutics (NASDAQ:RAPT) Sets New 12-Month HighTime to Buy? - MarketBeat
How RAPT Therapeutics Inc. (0RA) stock performs in volatility spikesJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Will RAPT Therapeutics Inc. stock maintain growth story2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Published on: 2025-10-02 21:38:33 - newser.com
Will RAPT Therapeutics Inc. (0RA) stock draw ESG focused fundsRisk Management & Daily Profit Focused Screening - newser.com
Clear Street Maintains RAPT Therapeutics (RAPT) Buy Recommendation - Nasdaq
Clear Street Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $41 - 富途牛牛
Published on: 2025-09-30 02:47:57 - newser.com
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial - Investing.com Australia
Clear Street Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Raises Target Price to $41 - 富途牛牛
Rapt Therapeutics stock price target raised to $41 from $24 at Clear Street - Investing.com Canada
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):